What is he best known for?
The fields of study he is best known for:
- Gene
- Cancer
- Internal medicine
Peter S. Nelson mostly deals with Prostate cancer, Cancer research, Prostate, Internal medicine and Androgen receptor.
His study with Prostate cancer involves better knowledge in Cancer.
His Cancer research research includes elements of Carcinogenesis, Gene, Signal transduction and Immunology.
His Prostate research integrates issues from Stromal cell and Tissue microarray.
His Internal medicine study incorporates themes from Endocrinology and Oncology.
His study explores the link between Androgen receptor and topics such as Dihydrotestosterone that cross with problems in Dehydroepiandrosterone.
His most cited work include:
- Circulating microRNAs as stable blood-based markers for cancer detection (5780 citations)
- Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor (2121 citations)
- Integrative clinical genomics of advanced prostate cancer (1675 citations)
What are the main themes of his work throughout his whole career to date?
Peter S. Nelson spends much of his time researching Prostate cancer, Cancer research, Internal medicine, Prostate and Androgen receptor.
To a larger extent, he studies Cancer with the aim of understanding Prostate cancer.
The Cancer research study combines topics in areas such as Phenotype, Carcinogenesis, Immunology, LNCaP and PTEN.
His study in Internal medicine is interdisciplinary in nature, drawing from both Endocrinology and Oncology.
The study incorporates disciplines such as Erg, Gene expression, Bioinformatics and Adenocarcinoma in addition to Prostate.
His work carried out in the field of Androgen receptor brings together such families of science as Receptor, Abiraterone acetate, Signal transduction and Tumor progression.
He most often published in these fields:
- Prostate cancer (101.18%)
- Cancer research (55.89%)
- Internal medicine (51.01%)
What were the highlights of his more recent work (between 2018-2021)?
- Prostate cancer (101.18%)
- Cancer research (55.89%)
- Androgen receptor (35.86%)
In recent papers he was focusing on the following fields of study:
Peter S. Nelson focuses on Prostate cancer, Cancer research, Androgen receptor, Internal medicine and Oncology.
His study on Prostate cancer is covered under Cancer.
His Cancer research research integrates issues from Cell, DNA damage, Transcriptome, Castration resistant and Metastasis.
His Androgen receptor research incorporates elements of Testosterone, Regulation of gene expression, Downregulation and upregulation and Kinase.
His research in the fields of Cohort, Abiraterone, Prostate-specific antigen and Survival analysis overlaps with other disciplines such as Score test.
The various areas that Peter S. Nelson examines in his Oncology study include Exome sequencing, DNA sequencing, Disease and MEDLINE.
Between 2018 and 2021, his most popular works were:
- Genomic correlates of clinical outcome in advanced prostate cancer. (233 citations)
- TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention? (136 citations)
- Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy. (85 citations)
In his most recent research, the most cited papers focused on:
The scientist’s investigation covers issues in Prostate cancer, Cancer research, Androgen receptor, Internal medicine and Prostate.
He combines Prostate cancer and TMPRSS2 in his studies.
His biological study spans a wide range of topics, including Cancer, Metastasis, Suppressor, DNA repair and Bone marrow.
He has included themes like Androgen deprivation therapy and Downregulation and upregulation, Gene in his Androgen receptor study.
Peter S. Nelson regularly ties together related areas like Oncology in his Internal medicine studies.
His Prostate research is multidisciplinary, relying on both Prospective cohort study, Cohort study and Urology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
